Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer buys Abbott Laboratories drug tests

Bayer buys Abbott Laboratories drug tests

1st February 2006

Abbott Laboratories has granted Bayer Healthcare Diagnostics Division, a member of the Bayer group, rights to new cancer and transplant drug tests.

Bayer has been granted licences to free PSA and tacrolimus tests and intends to develop these two new immediately.

Dr Samir Taneja, director of urologic oncology at the NYU Cancer Institute, said: “By adding free PSA to the oncology portfolio, Bayer HealthCare Diagnostics will have a very comprehensive diagnostic menu for prostate cancer markers.”

Tom Warekois, of Bayer Diagnostics, said: “The addition of fPSA and tacrolimus to our assay offering will enhance the laboratories’ ability to increase their test offering while optimizing their overall efficiency.

“This is another example of Bayer HealthCare Diagnostics’ commitment to expanding the test offering for immunosuppression drugs. Tacrolimus is complimentary to cyclosporine which is currently also in development and scheduled to release in 2006.”

The tacrolimus test is used with liver transplant patients, while the free PSA test can give information about whether a patient is at an increased risk of having prostate cancer.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.